LEXINGTON, Mass. and AMSTERDAM, June  22, 2026  (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

QURE

uniQure Announces $150 Million Proposed Public Offering

UniQure to raise $150 million via offering; potential QURE dilution

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>LEXINGTON, Mass. and AMSTERDAM, June  22, 2026  (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>UniQure announced a $150 million underwritten public offering, with a 30-day option to raise up to $22.5 million more via pre-funded warrants. Leerink Partners and Stifel are among the managers. The move signals ongoing capital-raising activity in the gene-therapy space and could imply near-term dilution pressure for peers like QURE if market sentiment weakens on finance activity.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>UniQure launches a $150M share offering with pre-funded warrants. 30-day option to buy up to $22.5M.</li><li>Leerink Partners and Stifel serve as bookrunning managers. Deal is subject to market conditions.</li><li>Shelf registration on Form S-3; preliminary prospectus to be filed with the SEC. Filed Jan 7, 2025.</li><li>UniQure notes hemophilia B approval as a milestone; pipeline targets Huntington&#039;s, temporal lobe epilepsy, Fabry.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>uniQure N.V. (QURE)</strong>: Announced the public offering; dilution could pressure near-term equity value.</li><li><strong>Leerink Partners LLC</strong>: Bookrunning manager; potential market makers’ implications on pricing.</li><li><strong>Stifel, Nicolaus &amp; Company</strong>: Co-manager for the offering; similar near-term market impact considerations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article describes a capital-raising event by a peer in the same sector, which can influence sector sentiment and valuation peers, including QURE.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Biotech fund-raising momentum in 2H 2026 could drag gene-therapy equities lower.</li><li>Dilution concerns may weigh on near-term valuations of peer names, including QURE.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Offering size: $150 million; additional up to $22.5 million via option.</li><li>Underwriters: Leerink Partners and Stifel; 30-day overallotment window.</li><li>Shelf registration: Form S-3; filed January 7, 2025.</li><li>Date of release: June 22, 2026; preliminary prospectus to be filed with SEC.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral to slightly bearish for QURE in 1–3 months on sector-wide dilution headlines and funding activity.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">LEXINGTON, Mass. and AMSTERDAM, June  22, 2026  (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/QURE">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>  <p align="justify">Leerink Partners and Stifel are acting as bookrunning managers for the proposed offering.</p>  <p align="justify">The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the "SEC") on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at <a href="https://www.globenewswire.com/Tracker?data=8soP5u8-HoROjGM5hU8StGg2rMEyV5_ByLm_XSFzgk5zXCgjtlifN4XDgmVPhdq4DXoaJYIfw0AJVLRP8xHxvg==" rel="nofollow" target="_blank">http://www.sec.gov</a>. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at <a href="https://www.globenewswire.com/Tracker?data=YVD0tq0bWpvd6xnMjI5x4bYQdWJ5NmWHlEyOHVSlQ1Rhahl6_HRNDflRrvGM4blBB3gATalhHOBBFDRVIG60HoJua_Lml3u2Seb7TRDXSh8=" rel="nofollow" target="_blank">syndicate@leerink.com</a>; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at <a href="https://www.globenewswire.com/Tracker?data=ffn8uDIqTl--gg1V0Nkha9elH5yUMDmYua1C00NNBMYKD_O2W0lcqctiSIu5ATXpNAt5qeShsC3DmJnHNgIwJ-AHNT7SDDPUISo19VWhrDN31DOwTWyC-9R0B3hpuvJ5" rel="nofollow" target="_blank">syndprospectus@stifel.com</a>.The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.</p>  <p align="justify">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.</p>  <p align="justify"><strong>About uniQure </strong></p>  <p align="justify">uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington&#39;s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.</p>  <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>  <p align="justify"><em>This press release contains certain &#34;forward-looking statements&#34; within the meaning of the &#34;safe harbor&#34; provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion, timing, and size of uniQure’s anticipated public offering, the grant to the underwriters of an option to purchase additional securities, and other statements identified by words such as &#34;estimate,&#34; &#34;plan,&#34; &#34;project,&#34; &#34;forecast,&#34; &#34;intend,&#34; &#34;will,&#34; &#34;shall,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;seek,&#34; &#34;target,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;may,&#34; &#34;might,&#34; &#34;possible,&#34; &#34;potential,&#34; &#34;predict&#34; and similar words or expressions.</em></p>  <p align="justify"><em>Forward-looking statements are based on management&#39;s beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or at all, continued interest in our rare disease portfolio, the ability to develop our product candidates and technologies, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading &#34;Risk Factors&#34; in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on March 2, 2026, our Quarterly Report on Form 10-Q filed on May 5, 2026, the preliminary prospectus supplement once filed with the SEC and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.</em></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:45%; width:45%; min-width:45%;;vertical-align: bottom ; "><strong>uniQure Contacts<br></br><br></br>For Investors:<br></br><br></br>Chiara Russo<br></br></strong>Direct: 781-491-4371<br></br>Mobile: 617-306-9137<br></br><a href="mailto:c.russo@uniQure.com" rel="nofollow" target="_blank">c.russo@uniQure.com</a><br></br></td><td style="max-width:55%; width:55%; min-width:55%;;vertical-align: bottom ; "><strong>For Media:<br></br><br></br></strong><strong>Tom Malone<br></br></strong>Direct: 339-970-7758<br></br>Mobile: 339-223-8541<br></br><a href="mailto:t.malone@uniQure.com" rel="nofollow" target="_blank">t.malone@uniQure.com</a><br></br></td></tr></table><img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MDU5NSM3NjcyNTAyIzIwODA0MDY="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NWVhN2UwOTgtNTkzMy00ODgwLTk2YWMtNjBjNDhiNjkwN2Y0LTEwOTE5NzctMjAyNi0wNi0yMi1lbg==/tiny/uniQure-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/2ba61fe2-12e5-4a01-afe1-419652b31512"><img src="https://ml.globenewswire.com/media/2ba61fe2-12e5-4a01-afe1-419652b31512/small/logo-uniqure-ms-word-orange-jpg.jpg" border="0" width="150" height="48" alt="Primary Logo"></img></a></p>

UniQure announced a $150 million underwritten public offering, with a 30-day option to raise up to $22.5 million more via pre-funded warrants. Leerink Partners and Stifel are among the managers. The move signals ongoing capital-raising activity in the gene-therapy space and could imply near-term dilution pressure for peers like QURE if market sentiment weakens on finance activity.

uniQure Announces $150 Million Proposed Public Offering

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News